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Introduction {#sec007}
============

Dementia refers to a group of neurological disorders characterized by memory loss, cognitive impairment, and disability in activities of daily living. As the primary risk factor for dementia is old age, the prevalence of dementia is increasing dramatically with aging populations worldwide. As no effective preventive treatment is currently available, the societal burden of dementia is huge and threatening to increase further \[[@pmed.1002265.ref001]\]. The most common form is Alzheimer disease (AD), a neurodegenerative disease representing 50%--70% of dementia cases. Cerebrovascular disease is also a major contributor to dementia risk, often in conjunction with neurodegenerative lesions \[[@pmed.1002265.ref002]\]. Vascular risk factors have been proposed as important targets for the prevention of dementia, with around a third of AD cases being attributable to potentially modifiable risk factors, especially vascular risk factors \[[@pmed.1002265.ref003],[@pmed.1002265.ref004]\], although trials have been inconclusive so far. As lipid fractions represent easily modifiable potential targets for prevention, exploring their relation with dementia risk is of major interest. So far, published studies have shown inconsistent results, including associations of adverse lipid profiles with an increased dementia risk \[[@pmed.1002265.ref005]--[@pmed.1002265.ref010]\], absence of an association \[[@pmed.1002265.ref011]--[@pmed.1002265.ref017]\], or even inverse associations \[[@pmed.1002265.ref018]--[@pmed.1002265.ref020]\]. Important differences between studies---regarding the timing of the measurement of lipid fraction in relation to the diagnosis of dementia, the age at which plasma lipid concentrations were measured, and the duration of follow-up---might at least partly explain these discrepancies. Significant associations of high cholesterol concentrations with dementia \[[@pmed.1002265.ref006]\], AD \[[@pmed.1002265.ref007]--[@pmed.1002265.ref010]\], or dementia death \[[@pmed.1002265.ref021],[@pmed.1002265.ref022]\] are described mostly in studies where lipid concentrations were measured in midlife and/or participants were followed for a long period until advanced late life, hence with a long exposure to high cholesterol concentrations. In contrast, studies with lipid measurements in later life or short follow-up periods not reaching the ages at which dementia prevalence is highest either do not observe any association \[[@pmed.1002265.ref004],[@pmed.1002265.ref013]--[@pmed.1002265.ref015]\] or sometimes observe inverse relations with dementia risk \[[@pmed.1002265.ref018],[@pmed.1002265.ref019]\]. Moreover, most studies have focused either on total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) or on triglycerides (TGs) and high-density lipoprotein cholesterol (HDL-C); few studies have studied all fractions simultaneously in the same dataset. Interestingly, we and others have recently shown that lipid fractions, notably higher TG concentrations, are significantly associated with white matter hyperintensity (WMH) volume on brain MRI \[[@pmed.1002265.ref023]--[@pmed.1002265.ref025]\], a powerful predictor of dementia risk \[[@pmed.1002265.ref026]\]. In the present work, we aimed to evaluate the relationship of lipid fractions (TGs, HDL-C, LDL-C, and TC) with incident dementia in a large cohort of community-dwelling older individuals over a follow-up period of 13 y.

Methods {#sec008}
=======

Ethics statement {#sec009}
----------------

The Ethics Committee of Kremlin-Bicêtre University Hospital approved study protocols, and each participant signed a written informed consent.

Study population {#sec010}
----------------

The Three-City Study (3C Study) is a longitudinal, population-based prospective cohort study, described in detail elsewhere \[[@pmed.1002265.ref027]\]. Briefly, 9,294 non-institutionalized persons aged 65+ y were recruited from the electoral rolls of Dijon, Bordeaux, and Montpellier, France, between March 1999 and March 2001. Extensive follow-up examinations were performed every 2 y after the baseline assessment, comprising standardized questionnaires, clinical examinations, and detailed cognitive assessment. The third follow-up examination consisted of a self-questionnaire or a phone interview for participants who had refused to or could not fill in the questionnaire. We excluded participants with brain tumor (*n =* 8), prevalent dementia (*n =* 214), or missing data for either lipid concentrations (*n =* 556) or educational level (*n =* 5). We also removed participants with Mini-Mental State Examination (MMSE) score less than 24 at baseline (*n =* 432) or with missing data for MMSE (*n =* 40), as these individuals might have had an undiagnosed dementia, with lipid concentrations already impacted by metabolic changes secondary to the disease \[[@pmed.1002265.ref028]\], thus leading to a sample of 8,039 participants at baseline. Incident dementia cases were prospectively ascertained over a 13-y follow-up period. Follow-up data on the outcome of interest were available in 7,470 of the 8,039 participants (\>92.9%), comprising our final study sample (see [S1 Fig](#pmed.1002265.s001){ref-type="supplementary-material"}).

Outcome ascertainment and definition of variables {#sec011}
-------------------------------------------------

### Dementia ascertainment {#sec012}

Dementia status was evaluated prospectively by an expert panel. In Bordeaux and Montpellier, all participants were examined by a neurologist. In Dijon, due to the large number of participants, a two-step procedure was used \[[@pmed.1002265.ref027]\]: (i) a careful neuropsychological evaluation carried out by a trained psychologist and (ii) an examination by a neurologist for those who screened positive at step 1 based on MMSE and Isaacs' Set Test, a measure of verbal fluency and response rapidity that consists of generating words belonging to given semantic categories (e.g., animal names) in 15 s \[[@pmed.1002265.ref027]\]. Isaacs' Set Test has been reported to show the earliest decline in the decade preceding dementia diagnosis \[[@pmed.1002265.ref029],[@pmed.1002265.ref030]\]. Cutoff scores were defined according to educational level as previously described \[[@pmed.1002265.ref031]\]. Finally, in all centers, the diagnosing examination and subtype classification of all suspected prevalent and incident dementia cases were performed by an independent committee of neurologists following DSM-IV criteria \[[@pmed.1002265.ref027],[@pmed.1002265.ref032]\]. The final diagnosis of dementia and subtype was made based on all available information, including data on cognitive functioning and daily activities, severity of cognitive disorders (Clinical Dementia Rating Scale), and, where possible, hospitalization records, CT scans (which were most often used at the beginning of the follow-up period) and magnetic resonance images \[[@pmed.1002265.ref027]\], and functional assessment, which included assessment of disabilities using the Katz Index of Activities of Daily Living \[[@pmed.1002265.ref033]\], the Lawton Instrumental Activities of Daily Living Scale \[[@pmed.1002265.ref034]\], and the Rosow and Breslau scales \[[@pmed.1002265.ref027],[@pmed.1002265.ref035]\]. Dementia subtypes included AD, vascular dementia, and mixed dementia. Due to small numbers in the last two categories, these were pooled for analyses. Dementia subtyping was based, for AD, on National Institute of Neurological and Communicative Disorders and Stroke--Alzheimer's Disease and Related Disorders Association criteria, and, for vascular dementia, on National Institute of Neurological Disorders and Stroke--Association Internationale pour la Recherche et l'Enseignement en Neurosciences criteria \[[@pmed.1002265.ref036],[@pmed.1002265.ref037]\]. Mixed dementia was defined as diagnosis of AD with either cerebrovascular lesions on brain imaging or a documented history of stroke and presence of prominent executive function deficits in addition to an AD-type cognitive profile.

### Laboratory testing {#sec013}

Centralized measurements of baseline fasting serum TC, HDL-C, and TG were performed using enzymatic methods. LDL-C was calculated with the Friedewald formula \[[@pmed.1002265.ref038]\] (LDL-C = TC − HDL-C − \[TGs/2.2\]) and was considered missing for TG values \> 400 mg/dl (4.52 mmol/l).

### Covariates {#sec014}

The following covariates were measured at baseline. Hypertension was defined by systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg or antihypertensive drug intake. Body mass index (BMI) was calculated as the ratio of weight (in kilograms) to the square of height (in meters). Diabetes was defined as fasting blood glucose ≥ 7 mmol/l or antidiabetic drug intake or medical history of diabetes. Hypercholesterolemia was defined as fasting TC ≥ 6.2 mmol/l or lipid-lowering drug intake (fibrate, statin, or bile acid sequestrant). Smoking status was categorized as never, former, or current smoker. History of cardiovascular disease was defined as a history of stroke, myocardial infarction, angina pectoris, or peripheral artery disease. Methods for genotyping the *APOE* epsilon polymorphism have been described previously \[[@pmed.1002265.ref039]\]. *APOE*ε4 carrier was defined as the presence of at least one ε4 allele. Educational level at baseline was defined as a six-class variable (no education, primary school, secondary school with certificate of vocational aptitude, secondary school with secondary education certificate, baccalaureate or equivalent, university or equivalent).

Statistical analyses {#sec015}
--------------------

To study the association between baseline lipid concentrations and 13-y incident dementia, we used Cox models, using age as time scale and birth as time origin. This allowed us to avoid the non-proportionality of dementia risk with age \[[@pmed.1002265.ref040]\]. Baseline age was the age at which participants entered the cohort. Data were censored at the age of dementia diagnosis for cases (median of the interval of the last follow-up visit without dementia and the first follow-up visit with dementia) or at age at last follow-up for controls. This model also accounted for left truncation and corrected for the bias introduced by including at baseline only individuals who did not develop dementia before inclusion. We verified the proportional hazard assumption using proportionality tests that assess the statistical significance of interaction terms between time (age at last follow-up or dementia occurrence) and the variables in the model. Since this assumption was not verified for educational level and antihypertensive drug intake, all Cox models also included an interaction term for these covariates with time (the interaction with antihypertensive drug intake being present only in models adjusted for vascular risk factors). Analyses were initially adjusted for study center, sex, educational level, and interaction between educational level and time (Model 1). Then additional adjustments were made for (i) vascular risk factors: BMI, systolic blood pressure, anti-hypertensive drug intake, interaction between antihypertensive drug intake and time, smoking status, diabetes, lipid-lowering drug intake, other lipid concentrations (analyses on TC were adjusted for TGs), and history of cardiovascular disease (model 2) and (ii) vascular risk factors and *APOE*ε4 genotype (model 3). Lipid concentrations were studied as continuous variables, and results are reported per increase in standard deviation (SD) of each lipid fraction. Of note, TG concentrations were log-transformed for analyses to remove skewness. When examining dementia subtypes, all subtypes that were not the primary outcome of interest were censored at the age of their diagnosis. We corrected for multiple testing by accounting for the number of independent lipid phenotypes examined, based on a previously described method \[[@pmed.1002265.ref041]\], yielding a significance threshold of 0.0169 (based on a family-wise error rate of 0.05 and three independent tests) that was applied to all analyses. *p*-Values greater than 0.0169 but less than 0.05 were considered nominally significant.

In secondary analyses, we first replaced overall lipid-lowering drug intake by statin intake when adjusting for vascular risk factors. Second, we ran sensitivity analyses censoring non-demented individuals at the age at last follow-up or age at death, instead of age at last follow-up only, in order to account for the competing risk of death. Third, we also performed Cox models using time-on-study as the time scale in order to generate cumulative incidence graphs adjusted for age, sex, and education and stratified on lipid concentration (top quartile \[or bottom quartile for HDL-C\] versus the rest). Fourth, we examined the robustness of our results by stratifying on *APOE*ε4 carrier status, lipid-lowering drug intake, sex, median age, or educational level (using a dichotomized variable coding no education/primary school versus the rest) and formally tested for interaction with these variables. Fifth, we examined in greater depth the impact of lipid-lowering drug intake on associations. As the effect of lipid-lowering drugs on AD was reported to vary by sex \[[@pmed.1002265.ref042]\], we also ran the analyses adjusted for lipid-lowering drug intake stratified by sex. Also, to take into account not only lipid-lowering drug intake but also the effect of lipid-lowering drugs on lipid concentrations, we stratified analyses on a three-class variable crossing lipid-lowering drug intake and TC concentration at baseline (i.e., no lipid-lowering drug intake, lipid-lowering drug intake and TC concentration at baseline \< 6.2 mmol/l, lipid-lowering drug intake and TC concentration at baseline ≥ 6.2 mmol/l). Sixth, we explored the relationship between sex-specific lipid quartiles and dementia risk, and linearity was assessed using the method based on Cox models as described above. The hazard ratio (HR) of each class of the lipid fraction divided in four classes, in each of which lipid concentrations were replaced by the value of the mean of the corresponding quartile minus that of the first quartile, was compared to the confidence interval of the HR of the corresponding quartile. The log-linearity hypothesis is acceptable if the HRs calculated for the classes are included in the confidence intervals from the corresponding quartile \[[@pmed.1002265.ref043]\]. We also used plots of cumulative Martingale residuals against the continuous variable of interest (LDL-C, TC, or TG) \[[@pmed.1002265.ref044]\].

Analyses were performed using SAS software version 9.3 (SAS Institute).

Results {#sec016}
=======

Our sample comprised 7,470 individuals, the characteristics of whom are described in [Table 1](#pmed.1002265.t001){ref-type="table"}. Compared to individuals who could not be included in the present study, individuals included were younger; were less likely to have hypercholesterolemia, hypertension, diabetes, and a history of cardiovascular disease; and were less likely to be *APOE*ε4 carriers, but were more likely to take lipid-lowering medication. Included individuals also had lower TG and higher HDL-C concentrations, lower systolic and diastolic blood pressures, a higher educational level, and a higher MMSE score at baseline. As expected, lipid fractions were correlated with one another, the strongest correlations being observed between LDL-C and TC, and between TG and HDL-C ([S1 Table](#pmed.1002265.s003){ref-type="supplementary-material"}).

10.1371/journal.pmed.1002265.t001

###### Baseline characteristics of 3C participants.

![](pmed.1002265.t001){#pmed.1002265.t001g}

  Characteristic                                                                  Individuals included in analyses, *n =* 7,470   Individuals not included in analyses[\*](#t001fn002){ref-type="table-fn"}, *n =* 1,824   *p*-Value
  ------------------------------------------------------------------------------- ----------------------------------------------- ---------------------------------------------------------------------------------------- ------------------------------------------------
  **Age, years**                                                                  73.83 ± 5.32                                    76.29 ± 6.30                                                                             \<0.0001
  **Women**                                                                       4,558 (61.02)                                   1,086 (59.54)                                                                            0.2466
  **Triglycerides, mmol/l**[\*\*](#t001fn003){ref-type="table-fn"}                1.25 ± 0.61                                     1.34 ± 0.68[^‡^](#t001fn004){ref-type="table-fn"}                                        \<0.0001
  **Total cholesterol concentration, mmol/l**                                     5.82 ± 0.97                                     5.81 ± 1.08[^‡^](#t001fn004){ref-type="table-fn"}                                        0.6979
  **HDL-C concentration, mmol/l**                                                 1.62 ± 0.40                                     1.55 ± 0.43[^‡^](#t001fn004){ref-type="table-fn"}                                        \<0.0001
  **LDL-C concentration, mmol/l**                                                 3.63 ± 0.85                                     3.64 ± 0.93[^‡^](#t001fn004){ref-type="table-fn"}                                        0.7313
  **Hypercholesterolemia**                                                        4,258 (57.00)                                   845 (59.97)[^‡^](#t001fn004){ref-type="table-fn"}                                        0.0386
  **Lipid-lowering drug intake**                                                  2,298 (30.76)                                   495 (27.14)                                                                              0.0025
  **Systolic blood pressure, mm Hg**                                              146.34 ± 21.64                                  147.70 ± 22.63                                                                           0.0207
  **Diastolic blood pressure, mm Hg**                                             82.36 ± 11.20                                   81.58 ± 11.97                                                                            0.0128
  **Hypertension**                                                                5,732 (76.73)                                   1,473 (81.34)                                                                            \<0.0001
  **Ever smoker**                                                                 2,890 (38.70)                                   696 (38.20)                                                                              0.6921
  **Diabetes**                                                                    696 (9.35)                                      216 (16.65)[^‡^](#t001fn004){ref-type="table-fn"}                                        \<0.0001
  **BMI**                                                                         25.65 ± 4.00                                    25.68 ± 4.32                                                                             0.7477
  ***APOE*ε4 carrier**                                                            1,489 (20.03)                                   289 (23.27)[^‡^](#t001fn004){ref-type="table-fn"}                                        0.0089
  **History of cardiovascular disease**                                           661 (8.85)                                      247 (13.59)                                                                              \<0.0001
  **Educational level**                                                                                                                                                                                                    \<0.0001[^§^](#t001fn005){ref-type="table-fn"}
  No education                                                                    107 (1.43)                                      91 (5.02)                                                                                
  Primary school                                                                  2,194 (29.37)                                   710 (39.14)                                                                              
  No education/primary school categories combined                                 2,301 (30.80)                                   801 (44.16)                                                                              
  Secondary school with certificate of vocational aptitude                        993 (13.29)                                     319 (17.58)                                                                              
  Secondary school with secondary education certificate                           1,270 (17.00)                                   210 (11.58)                                                                              
  Secondary school categories combined                                            2,263 (30.29)                                   529 (29.16)                                                                              
  Baccalaureate or equivalent                                                     1,049 (14.04)                                   160 (8.82)                                                                               
  University or equivalent                                                        1,857 (24.86)                                   324 (17.86)                                                                              
  **Mini-Mental State Examination score**[^†^](#t001fn006){ref-type="table-fn"}   27.64 ± 1.55                                    25.11 ± 3.40                                                                             \<0.0001

Values are mean ± standard deviation or number (percentage). Body mass index (BMI) was calculated as the ratio of weight (in kilograms) to the square of height (in meters). Diabetes was defined as fasting blood glucose ≥ 7 mmol/l or antidiabetic drug intake or medical history of diabetes. Hypercholesterolemia was defined as fasting total cholesterol ≥ 6.2 mmol/l or lipid-lowering drug intake. Hypertension was defined as systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg or antihypertensive drug intake.

\*Excluded for brain tumor, prevalent dementia, or Mini-Mental State Examination score \< 24 at baseline, or missing data for lipid concentrations, educational level, Mini-Mental State Examination score, or follow-up data.

\*\*Triglycerides were log-transformed for analyses.

^‡^\>10% missing data.

^§^For the comparison of individuals with either no education or primary school versus the other categories.

^†^Number of good answers.

HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

Over the follow-up period (mean \[SD\] = 7.9 \[3.6\] y), 779 participants developed dementia, of which 532 were classified as AD, 95 as mixed dementia and 59 as vascular dementia (due to small numbers, mixed and vascular dementia were considered together), and 93 as other types of dementia (excluded). Higher LDL-C and TC concentrations at baseline were significantly associated with an increased risk of AD, and these associations were maintained after accounting for the competing risk of death and after adjustment for vascular risk factors, even after replacing lipid-lowering drug intake by statin intake (Tables [2](#pmed.1002265.t002){ref-type="table"}, [S2](#pmed.1002265.s004){ref-type="supplementary-material"} and [S3](#pmed.1002265.s005){ref-type="supplementary-material"}). Effect size and significance level were reduced after additionally adjusting for *APOE*ε4 genotype, but remained significant for the association of LDL-C and AD and nominally significant for the association of TC and AD (*p =* 0.0171, not significant according to our statistical criterion allowing for multiple testing) (Tables [2](#pmed.1002265.t002){ref-type="table"} and [S3](#pmed.1002265.s005){ref-type="supplementary-material"}). Higher TG concentration at baseline was associated with a significantly increased incidence of all and mixed or vascular dementia, even when accounting for the competing risk of death, except for the association with mixed or vascular dementia, which became nominally significant (*p =* 0.0188) (Tables [2](#pmed.1002265.t002){ref-type="table"} and [S3](#pmed.1002265.s005){ref-type="supplementary-material"}). These associations became nonsignificant after adjusting for vascular risk factors, with or without additional adjustment for *APOE*ε4 genotype, and replacing lipid-lowering drug intake by statin intake did not modify these results (Tables [2](#pmed.1002265.t002){ref-type="table"}, [S2](#pmed.1002265.s004){ref-type="supplementary-material"} and [S3](#pmed.1002265.s005){ref-type="supplementary-material"}).

10.1371/journal.pmed.1002265.t002

###### Associations between baseline lipid concentrations and 13-y incident dementia using Cox models.

![](pmed.1002265.t002){#pmed.1002265.t002g}

  Model and outcome                                                                                                                                                                                            TGs         HDL-C               LDL-C    TC                                                                                                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------- ------------------- -------- ----------- ------------------- -------- ----------- ------------------- -------- ----------- ------------------- --------
  **Model 1: adjusted for sex, education, center, education × log(age)**[^†^](#t002fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                            
  All dementia                                                                                                                                                                                                 778/7,466   1.11 (1.03, 1.19)   0.0044   779/7,467   0.92 (0.86, 1.00)   0.0431   776/7,440   1.07 (1.00, 1.15)   0.0511   779/7,470   1.07 (1.00, 1.15)   0.0563
  Alzheimer disease                                                                                                                                                                                            531/7,466   1.06 (0.97, 1.16)   0.1693   532/7,467   0.95 (0.87, 1.04)   0.2580   529/7,440   1.13 (1.04, 1.22)   0.0045   532/7,470   1.12 (1.03, 1.22)   0.0072
  Mixed or vascular dementia                                                                                                                                                                                   154/7,466   1.21 (1.04, 1.41)   0.0163   154/7,467   0.90 (0.76, 1.07)   0.2260   154/7,440   0.99 (0.85, 1.16)   0.9140   154/7,470   1.01 (0.86, 1.19)   0.8906
  **Model 2: adjusted for sex, education, center, education × log(age)**[^†^](#t002fn002){ref-type="table-fn"}**, vascular risk factors**[^‡^](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                           
  All dementia                                                                                                                                                                                                 761/7,376   1.05 (0.97, 1.15)   0.2424   761/7,376   0.98 (0.90, 1.08)   0.6924   761/7,376   1.10 (1.02, 1.18)   0.0153   762/7,402   1.09 (1.01, 1.18)   0.0263
  Alzheimer disease                                                                                                                                                                                            522/7,376   1.00 (0.90, 1.11)   0.9909   522/7,376   0.97 (0.87, 1.09)   0.6250   522/7,376   1.16 (1.06, 1.27)   0.0009   523/7,402   1.15 (1.05, 1.26)   0.0028
  Mixed or vascular dementia                                                                                                                                                                                   150/7,376   1.16 (0.95, 1.41)   0.1406   150/7,376   1.05 (0.85, 1.29)   0.6570   150/7,376   0.98 (0.83, 1.17)   0.8620   150/7,402   1.01 (0.85, 1.20)   0.9178
  **Model 3: adjusted for sex, education, center, education × log(age)**[^†^](#t002fn002){ref-type="table-fn"}**, vascular risk factors**[^‡^](#t002fn003){ref-type="table-fn"}**, *APOEε4* carrier status**                                                                                                                                                              
  All dementia                                                                                                                                                                                                 755/7,344   1.07 (0.98, 1.17)   0.1374   755/7,344   0.99 (0.91, 1.09)   0.8905   755/7,344   1.06 (0.99, 1.15)   0.1123   756/7,369   1.06 (0.98, 1.15)   0.1258
  Alzheimer disease                                                                                                                                                                                            518/7,344   1.02 (0.91, 1.13)   0.7669   518/7,344   0.99 (0.88, 1.10)   0.8280   518/7,344   1.12 (1.03, 1.23)   0.0110   519/7,369   1.12 (1.02, 1.23)   0.0171
  Mixed or vascular dementia                                                                                                                                                                                   149/7,344   1.17 (0.96, 1.42)   0.1206   149/7,344   1.07 (0.87, 1.32)   0.5050   149/7,344   0.96 (0.81, 1.14)   0.6130   149/7,369   0.99 (0.83, 1.18)   0.9101

Results are given per standard deviation of lipid fraction (TG = 0.417; LDL = 0.854; HDL = 0.401; TC = 0.974).

^†^Age represents age at last follow-up or dementia.

^‡^Vascular risk factors for HDL-C, LDL-C, TGs: the three lipid fractions, body mass index, antihypertensive drug intake, systolic blood pressure, lipid-lowering drug intake, smoking status, diabetes, history of cardiovascular disease, antihypertensive drug intake × log(age). Vascular risk factors for TC: TGs, body mass index, antihypertensive drug intake, systolic blood pressure, lipid-lowering drug intake, smoking status, diabetes, history of cardiovascular disease, antihypertensive drug intake × log(age);

HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TGs, triglycerides.

We ran secondary association analyses stratified on dementia risk factors and putative effect modifiers. HRs were in the same direction when stratifying by participants' *APOE*ε4 carrier status, use of lipid-lowering drugs, sex, or educational level (based on a dichotomized variable comparing individuals with no education or primary school versus the rest), and there was no significant interaction with any of these variables ([S4](#pmed.1002265.s006){ref-type="supplementary-material"}--[S10](#pmed.1002265.s012){ref-type="supplementary-material"} Tables). Adjustment for use of lipid-lowering drugs also yielded similar findings in sex-specific analyses ([S6 Table](#pmed.1002265.s008){ref-type="supplementary-material"}). Moreover, when using a three-class variable to account for the effect of lipid-lowering drug intake on lipid concentrations, higher LDL-C concentrations were significantly associated with an increased risk of AD both in participants not on lipid-lowering drugs and in participants on lipid-lowering drugs with high TC concentrations, but not in participants on lipid-lowering drugs with normal TC concentrations, though the interaction was only nominally significant (*p =* 0.0294) ([S10 Table](#pmed.1002265.s012){ref-type="supplementary-material"}). However, there was a nominally significant interaction with age for the relationship of TC and all dementia (*p =* 0.0313) or AD (*p =* 0.0468), significant associations being observed only in the group aged at least 73.1 y at baseline ([S4 Table](#pmed.1002265.s006){ref-type="supplementary-material"}).

No deviation from linearity was found for all significant associations of LDL-C, TC, and TG with incident dementia in Cox models. When studying the associations using lipid concentrations in sex-specific quartiles, individually, the top quartile (or bottom quartile for HDL-C) was significantly associated with an increased risk of dementia (AD for LDL-C and TC, all dementia for TG, and all dementia for HDL-C; [S11 Table](#pmed.1002265.s013){ref-type="supplementary-material"}) compared to the bottom reference quartile (top quartile for HDL-C). Age-, sex-, and education-adjusted cumulative dementia incidence graphs stratified on the top (or bottom for HDL-C) sex-specific quartile of each lipid fraction (versus the three other quartiles) are represented in [Fig 1](#pmed.1002265.g001){ref-type="fig"}. All associations reported as significant for continuous lipid fractions also showed significant trend tests relating sex-specific lipid quartiles to dementia risk, except for the relationship between LDL-C and AD, for which the trend was only nominally significant (*p =* 0.0420).

![Cumulative incidence of dementia according to lipid concentrations (triglycerides, HDL-C, LDL-C, total cholesterol).\
These graphs are based on age-, sex-, and education-adjusted Cox models (from which indicated *p*-values were extracted). TG: blue, \<1.44 mmol/l (women) or \<1.55 mmol/l (men), versus pink, ≥1.44 mmol/l (women) or ≥1.55 mmol/l (men); *p*-values: *p =* 0.0046 (all dementia), *p =* 0.2745 (AD), *p =* 0.0623 (mixed or vascular dementia). HDL-C: blue, \>1.46 mmol/l (women) or \>1.20 mmol/l (men), versus pink, ≤1.46 mmol/l (women) or ≤1.20 (men); *p*-values: *p =* 0.0528 (all dementia), *p =* 0.2599 (AD), *p =* 0.5250 (mixed or vascular dementia). LDL-C: blue, \<4.25 mmol/l (women) or \<4.00 mmol/l (men), versus pink, ≥4.25 mmol/l (women) or ≥4.00 mmol/l (men); *p*-values: *p =* 0.0065 (all dementia), *p =* 0.0028 (AD), *p =* 0.5691 (mixed or vascular dementia).TC: blue, \<6.60 mmol/l (women) or \<6.10 mmol/l (men), versus pink, ≥6.60 mmol/l (women) or ≥6.10 mmol/l (men); *p*-values: *p =* 0.0210 (all dementia), *p =* 0.0383 (AD), *p =* 0.3259 (mixed or vascular dementia). AD, Alzheimer disease; dem., dementia; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MoVD, mixed or vascular dementia; TC, total cholesterol; TG, triglycerides.](pmed.1002265.g001){#pmed.1002265.g001}

Discussion {#sec017}
==========

In a cohort comprising 7,470 community-dwelling older persons, of whom 779 developed dementia over 13 y, associations of higher LDL-C, TC, and TGs with incident dementia were observed. When looking at dementia subtypes, we observed distinct patterns for the different lipid fractions: higher baseline LDL-C and TC concentrations were associated with AD, while higher baseline TG concentrations were associated with vascular or mixed dementia. For LDL-C and TC, associations were unchanged after accounting for vascular risk factors, but were attenuated after adjusting for *APOE*ε4 carrier status. For TGs, the results were no longer significant after adjusting for vascular risk factors. HDL-C concentrations were not associated with risk of incident dementia or its subtypes.

The current literature concerning associations between lipid concentrations and incident dementia risk is conflicting. Several studies reported a significant association of higher TC concentrations with increased risk of all dementia \[[@pmed.1002265.ref006]\], AD \[[@pmed.1002265.ref007]--[@pmed.1002265.ref010]\], or dementia mortality \[[@pmed.1002265.ref021],[@pmed.1002265.ref022]\]. However, two studies (*n =* 3,264 and 382) reported inverse associations with AD \[[@pmed.1002265.ref018],[@pmed.1002265.ref019]\], and a number of publications reported no significant association with all dementia \[[@pmed.1002265.ref004],[@pmed.1002265.ref013]--[@pmed.1002265.ref015],[@pmed.1002265.ref045]\], AD \[[@pmed.1002265.ref011],[@pmed.1002265.ref012],[@pmed.1002265.ref014],[@pmed.1002265.ref015],[@pmed.1002265.ref045],[@pmed.1002265.ref046]\], or vascular dementia risk \[[@pmed.1002265.ref012],[@pmed.1002265.ref015],[@pmed.1002265.ref018]\]. Higher LDL-C concentrations were associated with an increased risk of vascular dementia in one study \[[@pmed.1002265.ref011]\], whereas most studies reported no significant associations with all dementia \[[@pmed.1002265.ref045]\], AD \[[@pmed.1002265.ref011],[@pmed.1002265.ref012],[@pmed.1002265.ref020],[@pmed.1002265.ref045]\], or vascular dementia risk \[[@pmed.1002265.ref012]\]. Most studies reported no significant relationship between TG concentration and risk of dementia \[[@pmed.1002265.ref012],[@pmed.1002265.ref016],[@pmed.1002265.ref017],[@pmed.1002265.ref047]\], AD \[[@pmed.1002265.ref005],[@pmed.1002265.ref012],[@pmed.1002265.ref016],[@pmed.1002265.ref047],[@pmed.1002265.ref048]\], or mixed or vascular dementia \[[@pmed.1002265.ref005],[@pmed.1002265.ref012],[@pmed.1002265.ref016],[@pmed.1002265.ref017],[@pmed.1002265.ref047]\]. Although two studies have reported an association of lower HDL-C concentration with increased risk of all dementia (*n =* 337) \[[@pmed.1002265.ref049]\] or AD (*n =* 1,130) \[[@pmed.1002265.ref020]\], the vast majority reported no significant associations with all dementia \[[@pmed.1002265.ref005],[@pmed.1002265.ref014],[@pmed.1002265.ref016],[@pmed.1002265.ref017],[@pmed.1002265.ref047]\], AD \[[@pmed.1002265.ref005],[@pmed.1002265.ref011],[@pmed.1002265.ref012],[@pmed.1002265.ref014],[@pmed.1002265.ref016],[@pmed.1002265.ref017],[@pmed.1002265.ref047]\], or vascular dementia risk \[[@pmed.1002265.ref005],[@pmed.1002265.ref012],[@pmed.1002265.ref016],[@pmed.1002265.ref017],[@pmed.1002265.ref047]\].

Considering that the mean age at dementia diagnosis is around 85 y \[[@pmed.1002265.ref050]\], and that the pathological processes leading to dementia start many years before clinical diagnosis \[[@pmed.1002265.ref051]\], the age when lipid concentrations are measured, the follow-up duration, and the age at the end of follow-up are critical when exploring the relation between lipid fractions and dementia risk. In the literature, studies reporting significant associations between lipid concentrations and dementia risk were mostly studies where lipid concentrations were measured in midlife and/or individuals were followed-up for a long period of time until advanced late life \[[@pmed.1002265.ref006]--[@pmed.1002265.ref010]\]. In our study, where lipid concentrations were assayed at the age of 65 y or older, we observed a nominally significant interaction with age at admission, with associations of lipid fractions with dementia risk being significant only in the older half of our sample (mean age 78.2 ± 3.9 y at baseline) \[[@pmed.1002265.ref050]\].

The mechanisms underlying the association between lipid fractions and dementia risk are speculative. First, associations between lipid fractions and dementia risk may be directly mediated by cerebrovascular disease. We previously reported that higher TG concentrations were associated with a higher risk and burden of MRI markers for cerebral small vessel disease (WMHs and lacunar infarcts) \[[@pmed.1002265.ref023]\]. Extensive WMHs and lacunar infarcts were repeatedly shown to be associated with dementia risk \[[@pmed.1002265.ref026],[@pmed.1002265.ref052]\], and especially with mixed or vascular dementia risk \[[@pmed.1002265.ref026]\]. This is consistent with the association pattern between TG concentrations and dementia we observed, including a significant association with mixed or vascular dementia that lost significance after adjusting for vascular risk factors (adjusting for MRI markers of cerebral small vessel disease was not possible as MRI measures were available only in a much smaller subset of the study population). Along the same lines, higher LDL-C concentrations were associated with increased risk of AD, but not mixed or vascular dementia, in line with the absence of significant association between higher LDL-C concentrations and MRI markers of cerebral small vessel disease \[[@pmed.1002265.ref023]\].

Second, the observed associations may be an indirect marker of the relation between dementia and the *APOE*ε4 allele, as APOE is both a key player in lipid metabolism \[[@pmed.1002265.ref053]\] and one of the strongest risk factors for dementia and AD (*APOE*ε4 allele*)* \[[@pmed.1002265.ref053],[@pmed.1002265.ref054]\]. The attenuation of the association between LDL-C or TC and dementia risk after adjusting for *APOE*ε4 status (both in terms of effect size and significance) supports this hypothesis. Other genetic factors may also play a role, such as variants in *ATP binding cassette subfamily A member 1* (*ABCA1)* that are genome-wide significant risk variants for both LDL-C concentration and AD; additional AD risk variants are located near genes involved in lipid metabolism, such as *sortilin-related receptor L1* (*SORL1*), *clusterin* (*CLU*), *ATP binding cassette subfamily A member 7* (*ABCA7*), *phosphatidylinositol-binding clathrin assembly protein* (*PICALM*), and *bridging integrator 1* (*BIN1*) \[[@pmed.1002265.ref055],[@pmed.1002265.ref056]\]. Whether variants in the aforementioned genes share associations with lipid fractions and AD via independent genetic effects on both phenotypes (pleiotropy) \[[@pmed.1002265.ref056]\] or rather reflect true causal associations between lipid fractions and AD is a debated question. Appropriately designed intervention studies may be required to address this question.

To date, results of available experimental studies do not allow us to draw any conclusion on the existence of a causal relation between dyslipidemia and dementia risk. Two trials have examined the impact of lipid-lowering drugs, specifically statins, on dementia or cognitive decline \[[@pmed.1002265.ref057],[@pmed.1002265.ref058]\]. The PROSPER trial (pravastatin versus placebo) showed no difference in global cognitive function (MMSE) at 4 y between patients on treatment and those on placebo \[[@pmed.1002265.ref059]\]. Likewise, there was no difference in the incidence of dementia or in cognitive performance after 5 y in the HPS trial (simvastatin versus placebo) \[[@pmed.1002265.ref060]\]. However, in both these trials, dementia or cognitive decline were only secondary outcomes, and follow-up was relatively short. In the present study, the cumulative incidence curves of dementia seem to start separating mostly after 5 y between participants with high versus low LDL-C and TC concentrations. This suggests that longer term reduction of cholesterol concentrations may be required to observe a difference, which may be challenging to implement in practice, although use of surrogate endpoints such as change in intermediate markers may be a way to circumvent this difficulty. Another challenge is that lipid-lowering drugs do not lower all lipid fractions homogeneously \[[@pmed.1002265.ref061],[@pmed.1002265.ref062]\]. Of note, longitudinal epidemiological studies have also failed to show a significant association of lipid-lowering drugs with dementia risk in a recent systematic review \[[@pmed.1002265.ref063]\], in line with our findings, although some studies have reported a beneficial effect \[[@pmed.1002265.ref064],[@pmed.1002265.ref065]\], with the limitations inherent to studying drug effects in an observational setting and with limited duration of follow-up in most studies, although mostly longer than in the trials.

Strengths of our study include the large size of this population-based sample, with prospective diagnosis of dementia over up to 13 y, gathering one of the largest numbers of incident cases in a single study, with expert-panel-based validation and subtyping of dementia cases. Of note, this sample of non-institutionalized volunteers is not perfectly representative of the French general population of the same age range, as individuals taking part in a cohort study with regular follow-up examinations are more likely to be health-conscious and to have fewer risk factors than individuals who do not. This limitation is common to all prospective population-based studies, regardless of the sampling method used. However, as suggested by the PAQUID study, population-based samples may become more representative of the general population after a long follow-up period \[[@pmed.1002265.ref066]\]. Another limitation is the fairly old age of our population at baseline, when lipid fractions were measured. Indeed, lipid concentrations can be modified by behavioral changes, the presence of comorbidities, or initiation of lipid-lowering therapy. Midlife lipid concentrations, which better reflect exposure to dyslipidemia over a lifespan, were not available \[[@pmed.1002265.ref028],[@pmed.1002265.ref067]\]. We were also limited by the fact that exposures (lipid fractions and lipid-lowering drugs) vary during follow-up, and this was not accounted for in the present study, since follow-up data on exposures were available only on a very limited and selected subsample of the population from Dijon, at 4 y of follow-up (those who underwent both baseline and follow-up brain MRIs, *n =* 1,564, with 109 incident dementia cases). Moreover, our study may be limited by interval censoring because of the way age at dementia diagnosis was assessed (median of the interval from the last follow-up visit without dementia to the first follow-up visit with dementia) \[[@pmed.1002265.ref068]\]. However, we did partially account for interval censoring by censoring non-demented participants at last date of follow-up instead of date of death (the latter yielded similar results in sensitivity analyses). Finally, we cannot exclude a possible survival bias, since individuals with major dyslipidemia may have died early of vascular disease, before being included in this study.

In summary, in a large population-based sample of older community-dwelling persons with 779 incident dementia cases occurring over up to 13 y of follow-up, we observed that higher LDL-C and TC concentrations were associated with an increased risk of AD. This association was independent of vascular risk factors and was attenuated but still significant after adjustment for *APOE*ε4 carrier status. This attenuation may indicate that these associations are, in part, an indirect marker of the relation between dementia and the *APOE*ε4 allele. If confirmed in independent samples, the observed independent associations may suggest that there is a rationale for better exploring the potential benefit of lipid-lowering drugs for preventing dementia in older community-dwelling persons by appropriately designed intervention studies.
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